AbbVie Q4 2024 Earnings Preview: Strong results expected on Skyrizi, Rinvoq growth trajectory
AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and Rinvoq.
Wells downgrades Vertex to Equal Weight on lack of catalysts
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
AbbVie's SWOT analysis: biopharmaceutical giant navigates post-Humira landscape
AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...
Piramal Pharma Ltd: Piramal Pharma Limited Announces Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...
Piramal Pharma Limited Announces Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...
Is AbbVie Stock a Buy?
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.